Critical Survey: Pressure Biosciences (PBIO) versus Harvard Bioscience (HBIO)

Harvard Bioscience (NASDAQ:HBIO) and Pressure Biosciences (OTCMKTS:PBIO) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Profitability

This table compares Harvard Bioscience and Pressure Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harvard Bioscience -4.18% 5.54% 2.89%
Pressure Biosciences -517.56% N/A -571.71%

Institutional and Insider Ownership

73.0% of Harvard Bioscience shares are owned by institutional investors. 7.6% of Harvard Bioscience shares are owned by insiders. Comparatively, 15.9% of Pressure Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Harvard Bioscience has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Pressure Biosciences has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Harvard Bioscience and Pressure Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience 0 0 2 0 3.00
Pressure Biosciences 0 0 0 0 N/A

Harvard Bioscience presently has a consensus target price of $9.50, indicating a potential upside of 137.50%. Given Harvard Bioscience’s higher possible upside, equities analysts clearly believe Harvard Bioscience is more favorable than Pressure Biosciences.

Valuation & Earnings

This table compares Harvard Bioscience and Pressure Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $101.88 million 1.46 -$860,000.00 $0.05 80.00
Pressure Biosciences $2.24 million 2.41 -$10.71 million N/A N/A

Harvard Bioscience has higher revenue and earnings than Pressure Biosciences.

Summary

Harvard Bioscience beats Pressure Biosciences on 9 of the 11 factors compared between the two stocks.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion controllers, temperature controllers, microincubation systems, and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions. Harvard Bioscience, Inc. markets its products in approximately 100 countries through sales organization, Websites, catalogs, and distributors to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Pressure Biosciences Company Profile

Pressure BioSciences, Inc. develops pressure cycling technology (PCT) solutions. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler NEP3229, HUB440, HUB880, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT-MicroCaps, PCT-Micro-Pestle, PULSE Tubes, and BaroFlex 8-well Processing Strips, as well as application specific kits. Pressure BioSciences, Inc. serves researchers at academic laboratories; government agencies; and biotechnology, pharmaceutical, and other life sciences institutions in the United States, Europe, and Asia. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply